Reuters logo
BRIEF-Chemocentryx says granted EU orphan drug designation for avacopan in treating patients with C3G
2017年5月23日 / 下午12点47分 / 5 个月内

BRIEF-Chemocentryx says granted EU orphan drug designation for avacopan in treating patients with C3G

May 23 (Reuters) - Chemocentryx Inc

* Says granted EU orphan drug designation for avacopan in treatment of debilitating kidney disease C3 glomerulopathy

* Says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in mid-2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below